U.S. FDA grants approval for Lupin's generic Tolvaptan tablets
Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for Tolvaptan tablets of different strengths.
It is the exclusive first-to-file for this product and consequently eligible for 180 days of generic drug exclusivity. The product will be manufactured at its Nagpur facility and launched soon, Lupin said on Thursday.
The approved product is bioequivalent to Otsuka Pharmaceutical Company's Jynarque Tablets 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease.
Tolvaptan tablets had an estimated annual sale of $1,467 million in the U.S. during 2024.
CEO Vinita Gupta said the development marks 'a significant entry into the nephrology segment' for the company.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
11 hours ago
- Time of India
India a global leader in health innovation and vaccines: Jitendra
New Delhi: Underscoring India's evolution into a global health leader, Jitendra Singh, minister of state for science & technology and earth sciences and MoS in the PMO, said India was now recognised globally as a leader in healthcare innovation, pharmaceutical manufacturing and vaccine development , exporting vaccines to over 100 countries under Vaccine Maitri . "As we move forward, such partnerships will be key in shaping the future of global health from India," he said at the Times Now Doctors Day Conclave 2025, powered by Lupin. Minister of state for health and family welfare Anupriya Patel laid out the Centre's ambitious vision for India@100 and said, "We are committed to creating a resilient, inclusive and technology-driven healthcare ecosystem by 2047, as we celebrate 100 years of independence. Our vision is to ensure accessible and affordable healthcare for every citizen. The National Health Policy embodies this vision, shifting the focus from disease-specific interventions to a comprehensive and integrated approach rooted in universal health coverage. This is a paradigm shift - one that redefines how we view health and well-being, not just within India but also in alignment with global priorities." Others who spoke at the event included Punjab governor and Chandigarh administrator Gulab Chand Kataria, Tripura governor Indrasena Reddy Nallu and Andhra Pradesh health minister Satya Kumar Yadav. Kataria said since 2014, India's healthcare budget had grown from Rs 33,000 crore to Rs 99,000 crore, reflecting the govt's strong commitment to a Swasth Bharat under the leadership of PM Narenrda Modi.
Time of India
12 hours ago
- Time of India
India a global leader in health innovation and vaccines: Jitendra
NEW DELHI: Underscoring India's evolution into a global health leader, Jitendra Singh, junior minister for science & technology and earth sciences, said India was now recognised globally as a leader in healthcare innovation, pharmaceutical manufacturing and vaccine development, exporting vaccines to over 100 countries under Vaccine Maitri. "As we move forward, such partnerships will be key in shaping the future of global health from India," he said at the Times Now Doctors Day Conclave 2025, powered by Lupin. Junior minister for health and family welfare Anupriya Patel laid out the Centre's ambitious vision for India@100 and said, "We are committed to creating a resilient, inclusive and technology-driven healthcare ecosystem by 2047, as we celebrate 100 years of independence. Our vision is to ensure accessible and affordable healthcare for every citizen. The National Health Policy embodies this vision, shifting the focus from disease-specific interventions to a comprehensive and integrated approach rooted in universal health coverage. This is a paradigm shift - one that redefines how we view health and well-being, not just within India but also in alignment with global priorities." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Learn About Hotel Management Courses in Switzerland and the UK LocalPlan Search Now Undo Others who spoke at the event included Punjab governor and Chandigarh administrator Gulab Chand Kataria, Tripura governor Indrasena Reddy Nallu and Andhra Pradesh health minister Satya Kumar Yadav. Kataria said since 2014, India's healthcare budget had grown from Rs 33,000 crore to Rs 99,000 crore, reflecting the govt's strong commitment to a Swasth Bharat under the leadership of PM Narenrda Modi. Nallu spoke about transforming access to affordable healthcare by scaling telemedicine services across the nation. TNN
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts
The Indian pharmaceutical industry is poised to benefit from a major wave of patent expiries in the US, with small-molecule drugs worth $63.7 billion expected to go off-patent between 2025 and 2029—a 65 per cent increase over the previous five years. Combined with a broader Loss of Exclusivity (LoE) opportunity across the US and EU projected to reach $180 billion by 2035, this marks a significant opening for Indian drugmakers, according to a report by Antique Stock Broking Limited. This shift is expected to spur a rise in generic launches, particularly benefiting Indian players with emerging US operations and expertise in complex generics. Firms such as Alembic Pharmaceuticals and Shilpa Medicare, which have smaller US footprints, and larger players like Cipla and Lupin, which have invested early in differentiated products such as injectables and respiratory therapies, are seen as well positioned to gain market share. With global majors like Teva, Viatris and Sandoz having closed dozens of manufacturing sites since 2018, Indian companies are stepping in to fill the supply gap. However, the opportunity is unfolding amid growing strategic discipline. Filings of Abbreviated New Drug Applications (ANDAs) in the US declined 25 per cent year-on-year. FY25 filings are projected to close around 550—down from 740 in FY24 and 857 in FY22. This signals a pivot from volume to portfolio quality, regulatory compliance and margin protection. Commenting on this shift, Nilaya Varma, Group CEO and Co-founder of Primus Partners, said, 'India's pharma exports have grown from $15 billion in 2013–14 to nearly $28 billion in a decade. With 750+ USFDA-approved plants and rising strength in complex generics and biosimilars, India is primed to lead the next wave of affordable, high-quality medicines. Tapping the $180 billion LoE opportunity will require continued focus on compliance and quality systems.' Regulatory headwinds are also easing. The share of US FDA inspections resulting in Official Action Indicated (OAI) for Indian firms has fallen from 19 per cent in 2013 to 9 per cent in 2023. Companies like Cipla are further de-risking their US supply chains by adopting multi-site manufacturing and digital quality systems. Cipla, which holds a robust US portfolio of 284 ANDA and NDA filings—175 of which are approved and 73 under review—is focusing on commercialisation-ready products, including PEPFAR-approved generics. The company is betting on complex respiratory and injectable therapies to drive growth. Pharma major Lupin, which continues to benefit globally from its blockbuster autoimmune biologic Etanercept, plans to finalise its US commercialisation strategy closer to the drug's 2029 patent expiry. Meanwhile, Sun Pharma, despite offering a conservative FY26 outlook amid global macro uncertainties, is expanding its oncology pipeline. Its recently acquired UNLOXCYT (cosibelimab) is expected to significantly contribute to US revenues. The company noted that Keytruda's upcoming patent expiry was already factored into the acquisition. UNLOXCYT targets only one of Keytruda's multiple indications, and Sun remains confident in its potential to become a meaningful contributor to its US specialty business. In parallel, Sun is also strengthening its immunotherapy portfolio through a global licensing agreement with Philogen.
